ESSA Pharma (NASDAQ:EPIX) Announces Quarterly Earnings Results

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) issued its quarterly earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05, Zacks reports.

ESSA Pharma Price Performance

ESSA Pharma stock opened at $1.63 on Tuesday. The company has a market cap of $72.32 million, a price-to-earnings ratio of -2.63 and a beta of 1.62. ESSA Pharma has a 12 month low of $1.40 and a 12 month high of $11.67. The stock’s 50-day moving average is $3.18 and its 200-day moving average is $4.67.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Oppenheimer lowered ESSA Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th. Jefferies Financial Group cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Finally, Piper Sandler lowered shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $2.00 in a research report on Monday, November 4th.

Insider Transactions at ESSA Pharma

In related news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of ESSA Pharma stock in a transaction on Friday, November 1st. The shares were sold at an average price of $1.53, for a total transaction of $12,055,761.99. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 14.70% of the company’s stock.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.